The American Chamber of Commerce in Korea convened about 150 officials and executives at its 17th Healthcare Innovation Seminar in Seoul, where government and industry leaders called for predictable i…
Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismeran Autogene, combined with the immunotherapy Keytruda, reduced the risk of melanoma recurrence by 49% within five years…
On August 15, Anthropic CEO Dario Amodei argued that AI companies will earn trust by curing diseases, and the past week showcased advances in AI-driven medicine, including Moderna and Merck's INTerpat…
Less than a quarter of S&P 500 companies had AI deeply integrated into their business processes or used in production and delivery by the end of last year, according to an analysis of corporate financ…
Wall Street's main indexes closed higher on Tuesday, with the Dow Jones Industrial Average rising 160.24 points (0.30%) to 53,577.40, the S&P 500 gaining 24.38 points (0.32%) to 7,677.24, and the Nasd…
Nvidia bröt en sju dagar lång nedgångssvit och vände uppåt inför onsdagskvällens rapportsläpp, vilket lyfte techsektorn och bidrog till att Nasdaq steg 0,7 procent medan S&P 500 och Dow Jones båda avs…
Moderna (MRNA) stock surged 177% to a three-year high on Wednesday after the Cambridge, Mass.-based company reported positive results in a cancer vaccine trial showing longer relapse times, and Invest…
Moderna and Merck's experimental mRNA cancer vaccine intismeran autogene met its primary endpoint of recurrence-free survival and a key secondary endpoint in a Phase 3 trial of 1,137 patients with res…
US stocks closed lower on Thursday, with the S&P 500 down 0.9%, Nasdaq down 1.0%, and Dow Jones down 1.3%, as rising bond yields and oil prices fueled inflation concerns. The VIX volatility index rose…
Merck and Moderna announced positive topline Phase 3 results for their personalized cancer treatment INTerpath-001, which uses AI to identify up to 34 neoantigens per patient and an mRNA vaccine to ta…
Billionaire entrepreneur Mark Cuban said on X that doctors should help patients configure AI tools such as Claude, ChatGPT, Gemini, and Grok for their treatment, arguing that AI will replace most doct…
AI-designed neoantigen vaccines have reached a Phase 3 milestone, with the pipeline from tumor sequencing to mRNA construct increasingly driven by machine learning tools such as NetMHCpan, MHCflurry, …
Tempus AI's $1.5 billion acquisition of Personalis, announced July 20, 2026, looks prescient after Moderna and Merck reported positive Phase 3 results for mRNA-4157, a personalized cancer vaccine that…
Lila Sciences, an AI-for-science company launched by Flagship Pioneering, has raised roughly $550 million, including a $200 million seed round from Flagship Pioneering with General Catalyst, March Cap…
The FDA approved mFLUSIVA, the first mRNA influenza vaccine licensed in the United States, on August 5, 2026, exactly one year after the Department of Health and Human Services canceled 22 mRNA vaccin…
Commonwealth Fusion Systems, the best-funded fusion startup, raised another $1 billion, bringing its total capital to $4 billion, roughly 30% of all money ever raised for fusion. The Massachusetts-bas…
Chip stocks slumped, dragging down the S&P 500 and Nasdaq 100, as AI-linked names lost steam. Oil prices fell on optimism over a potential peace deal reopening the Strait of Hormuz. Moderna rose on or…
A trial of XBOW's autonomous offensive security platform uncovered a vulnerability that led to a full takedown of a development environment used by Moderna. Security leaders say advanced AI models are…
XBOW's AI-powered security platform discovered a critical vulnerability in Moderna's development environment within hours, a task that would have taken human penetration testers significantly longer. …